var data={"title":"Travelersâ€™ diarrhea-cholera vaccine (United States: Not available): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Travelers&rsquo; diarrhea-cholera vaccine (United States: Not available): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/232354?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=travelers-diarrhea-cholera-vaccine-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">see &quot;Travelers&rsquo; diarrhea-cholera vaccine (United States: Not available): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3274459\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Dukoral</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3275023\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Vaccine;</li>\n      <li>\n        Vaccine, Inactivated (Bacterial)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6131824\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cholera: </b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Primary immunization:</i> 2 doses given at intervals of &ge;1 week and completed at least 1 week prior to trip to endemic/epidemic areas; restart primary immunization schedule if interval between doses &gt;6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Booster:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">2 to 5 years <b>since last dose</b>: 1 booster dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;5 years <b>since last dose</b>: Repeat primary immunization schedule</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patients with ongoing risk (off-label): 1 booster dose every 2 years (NACI 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>ETEC diarrhea:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Primary immunization:</i> 2 doses given at intervals of &ge;1 week and completed at least 1 week prior to trip to endemic/epidemic areas; restart primary immunization schedule if interval between doses &gt;6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Booster:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">3 months to 5 years <b>since last dose</b>: 1 booster dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;5 years <b>since last dose</b>: Repeat primary immunization schedule</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patients with ongoing risk (off-label): 1 booster dose every 3 months (NACI 2012)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50992132\" class=\"block dora drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50989388\" class=\"block doha drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6131823\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cholera:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Primary immunization:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 2 to &lt;6 years: 3 doses given at intervals of &ge;1 week and completed at least 1 week prior to trip to endemic/epidemic areas; restart primary immunization schedule if interval between any doses &gt;6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;6 years: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Booster:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 2 to &lt;6 years:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">6 months to 5 years <b>since last dose</b>: 1 booster dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&gt;5 years <b>since last dose</b>: Repeat primary immunization schedule</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patients with ongoing risk (off-label): 1 booster dose every 6 months (NACI 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;6 years: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>ETEC diarrhea:</b> Oral: Children &ge;2 years: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51220260\" class=\"block dorp drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Pediatric)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51220261\" class=\"block dohp drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Pediatric)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3275045\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5951005\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suspension [vial]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dukoral: 31.25 x 10<sup>9</sup> of each of the following <i>Vibrio cholerae</i> O1 strains: Inaba classic (heat inactivated), Inaba El Tor (formalin inactivated), Ogawa classic (heat inactivated), Ogawa classic (formalin inactivated), and 1 mg recombinant cholera toxin B subunit (rCTB) (3 mL) [may contain trace amounts of formaldehyde; packaged with sachet containing 5.6 g sodium hydrogen carbonate (contains saccharin, raspberry flavor)]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11234362\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Not available in the US</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3275046\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>For oral use only;</b> do not administer IM, IV, or SubQ. Oral administration of other medications, vaccines, and consumption of food or drink should be avoided 1 hour before and 1 hour following vaccine administration. Separate administration of typhoid vaccine (oral) by at least 8 hours.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3274761\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Not approved in the US</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cholera disease prevention</b>: Active immunization against cholera in adults and children &ge;2 years of age who will be visiting areas where there is a risk of contracting cholera caused by <i>V. cholerae</i> O1 (classical and El Tor biotypes; Inaba and Ogawa serotypes)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Enterotoxigenic </b>\n      <i>\n        <b>E. coli</b></i>\n      <b> diarrhea disease prevention: </b>Active immunization against travelers&rsquo; diarrhea in adults and children &ge;2 years of age who will be visiting areas where there is a risk of contracting travelers&rsquo; diarrhea caused by enterotoxigenic <i>E. coli</i> (ETEC) producing heat-labile enterotoxin (LT) (either LT alone or both LT and heat stable enterotoxin (ST) together)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> The Committee to Advise on Tropical Medicine and Travel (CATMAT) and the National Advisory Committee on Immunization (NACI) do not routinely recommend vaccination with Travelers&rsquo; diarrhea and Cholera vaccine for most travelers. Vaccination should be considered after a detailed, travel-related risk assessment to identify those most likely to benefit from vaccination (CATMAT 2015; NACI 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3275032\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">&lt;1%, postmarketing, and/or case reports: Abdominal cramps, abdominal distress, abdominal pain, angioedema, arthralgia, chills, cough, decreased appetite, dehydration, diaphoresis, diarrhea, dizziness, drowsiness, dysgeusia, dyspepsia, dyspnea, fatigue, fever, flatulence, flu-like symptoms, gastroenteritis, headache, hypertension, increased bronchial secretions, insomnia, lymphadenitis, malaise, nausea, pain, paresthesia, pruritus, rhinitis, shivering, skin rash, sore throat, syncope, urticaria, vomiting, weakness</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3275028\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to any component of the formulation or packaging or to formaldehyde; acute gastrointestinal illness or acute febrile illness (excluding minor illnesses such as a mild upper respiratory tract infection)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3275029\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactoid/Hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine administration (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acute illness: Use of travelers' diarrhea and cholera vaccine is contraindicated in patients with acute febrile or acute gastrointestinal illness. In general, vaccines may be administered in patients with mild or moderate acute illness (NACI 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cholera infection: Vaccine has not been shown to protect against cholera caused by <i>V. cholerae</i> serogroup O139 or other species of <i>Vibrio</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; HIV: Vaccine may be administered to patients with HIV infection. No specific studies have been conducted in this patient population; however, a field study exhibited 84% immunity in a population with ~25% HIV prevalence.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vaccines: In order to maximize vaccination rates, the NACI recommends simultaneous administration of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single clinic visit, unless contraindications exist (NACI 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Altered immunocompetence: Consider deferring immunization during periods of severe immunosuppression (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy [including high-dose corticosteroids]); may have a reduced response to vaccination. In general, household and close contacts of persons with altered immunocompetence may receive all age appropriate vaccines. Inactivated vaccines should be administered &ge;2 weeks prior to planned immunosuppression when feasible; inactivated vaccines administered during chemotherapy should be readministered after immune competence is regained (ACIP [Kroger 2017]; IDSA [Rubin 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Formaldehyde: Some dosage forms may contain trace amounts of formaldehyde.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Antipyretics: Antipyretics have not been shown to prevent febrile seizures. Antipyretics may be used to treat fever or discomfort following vaccination (ACIP [Kroger 2017]). One study reported that routine prophylactic administration of acetaminophen prior to vaccination to prevent fever decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Cholera vaccination: The World Health Organization (WHO) recommends vaccination, in conjunction with other preventive and control strategies (eg, provision of safe water and sanitation efforts), in endemic areas (eg, south and southeast Asia and Africa) and in areas at risk for outbreaks. Vaccination should be targeted at high-risk populations (eg, children) when resources are limited. Reactive vaccination may be considered to control the spread of current outbreaks. In addition, the WHO recommends vaccination for travelers who are at an increased risk for the disease (eg, emergency relief and health workers in refugee situations) (WHO 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval. Vaccines may not be effective if administered during periods of altered immune competence (ACIP [Kroger 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300162\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3275037\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9489&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Patients should receive inactivated vaccines prior to initiation of belimumab therapy whenever possible, due to the risk for an impaired response to the vaccine during belimumab therapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting fingolimod. If vaccinated during fingolimod therapy, revaccinate 2 to 3 months after fingolimod discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunosuppressants: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<b> Exceptions: </b>Cytarabine (Liposomal).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vedolizumab: May diminish the therapeutic effect of Travelers' Diarrhea and Cholera Vaccine. Management: Administer travelers' diarrhea andl cholera vaccine prior to initiation of therapy with vedolizumab.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venetoclax: May diminish the therapeutic effect of Vaccines (Inactivated).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3275038\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Food and/or drink may affect efficacy of the vaccine. Management: Avoid food and/or drink 1 hour before and 1 hour following vaccine administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3275024\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Safety and efficacy in pregnant women have not been established; the vaccine is not recommended for use during pregnancy. However, since the vaccine is given orally in an inactivated form, acts locally in the gut, and does not replicate, it may not (in theory) cause a risk to the fetus. Use should only be considered if the potential benefit to the mother outweighs the potential risk to the fetus. Inactivated vaccines have not been shown to cause increased risks to the fetus (ACIP [Kroger 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3275027\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">The manufacturer states that the vaccine may be given to lactating women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3276395\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;display:inline\">There is ~1.1 g of sodium per dose of vaccine.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10204253\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Contains killed <i>V. cholerae</i> O1 bacteria and recombinant cholera toxin B subunit (CTB); the toxin of enterotoxigenic <i>E. coli</i> (ETEC) is structurally, functionally, and immunologically similar to CTB and is neutralized by antibodies against CTB.  Vaccine administration induces immunity and an IgA antitoxic and antibacterial response locally within the gastrointestinal tract; immunity is specific to <i>V. cholerae</i> O1 (classical and El Tor biotypes; Inaba and Ogawa serotypes) and ETEC.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3275042\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: ETEC diarrhea and cholera immunity: ~1 week after primary immunization</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: ETEC immunity: 3 months after primary immunization; Cholera immunity: Children 2-6 years of age: 6 months after primary immunization; Children &ge;6 years and Adults: 2 years after primary immunization</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4301379\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Dukoral&reg; (CA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Canadian Committee to Advise on Tropical Medican and Travel (CATMAT) 2015. An Advisory Committee Statement. http://www.phac-aspc.gc.ca/tmp-pmv/catmat-ccmtmv/diarrhea-diarrhee-eng.php. Accessed March 14, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Canadian National Advisory Committee on Immunization (NACI). Canadian Immunization Guide, 2012. https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines.html. Accessed March 14, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21293327\"></a>Centers for Disease Control and Prevention (CDC). Recommendations of the Advisory Committee on Immunization Practices (ACIP): General recommendations on immunization. MMWR Recomm Rep. 2011;60(2):1-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/travelers-diarrhea-cholera-vaccine-united-states-not-available-drug-information/abstract-text/21293327/pubmed\" target=\"_blank\" id=\"21293327\">21293327</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dukoral (inactivated travellers' diarrhea and cholera vaccine) [Canadian product monograph]. Stockholm, Sweden: Valneva Sweden AB; December 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kroger AT, Duchin J, Vazquez M. General Best Practice Guidelines for Immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). <a href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf\" target=\"_blank\">https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf</a>. Accessed April 4, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prymula R, Siegrist CA, Chlibek R, et al. Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials. <i>Lancet. </i>2009;374(9698):1339-1350.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/travelers-diarrhea-cholera-vaccine-united-states-not-available-drug-information/abstract-text/19837254/pubmed\" target=\"_blank\" id=\"19837254\">19837254</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host [published online ahead of print]. <i>Clin Infect Dis</i>. 2014;58(3):e44-e100.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/travelers-diarrhea-cholera-vaccine-united-states-not-available-drug-information/abstract-text/24311479/pubmed\" target=\"_blank\" id=\"24311479\">24311479</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization, &ldquo;Cholera Vaccines: WHO Position Paper,&rdquo; <i>Wkly Epidemiol Rec</i>, 2010, 85(13):117-28.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/travelers-diarrhea-cholera-vaccine-united-states-not-available-drug-information/abstract-text/20349546/pubmed\" target=\"_blank\" id=\"20349546\">20349546</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization. International Health and Travel. Geneva, Switzerland, 2011. http://www.who.int/ith/en/</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9489 Version 81.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F3274459\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F3275023\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F6131824\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Adult)\" href=\"#F50992132\" class=\"outlineLink\">Dosing: Renal Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Adult)\" href=\"#F50989388\" class=\"outlineLink\">Dosing: Hepatic Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F6131823\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Pediatric)\" href=\"#F51220260\" class=\"outlineLink\">Dosing: Renal Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Pediatric)\" href=\"#F51220261\" class=\"outlineLink\">Dosing: Hepatic Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F3275045\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F5951005\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F11234362\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F3275046\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F3274761\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F3275032\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F3275028\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F3275029\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300162\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F3275037\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F3275038\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F3275024\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F3275027\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F3276395\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F10204253\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F3275042\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F4301379\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9489|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=travelers-diarrhea-cholera-vaccine-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">Travelers&rsquo; diarrhea-cholera vaccine (United States: Not available): Patient drug information</a></li></ul></div></div>","javascript":null}